Navigation Links
CalbaTech Announces $999,926 Reduction in Debt; First Adult Stem Cell Harvesting Scheduled
Date:3/31/2008

LAGUNA HILLS, Calif., March 31 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), the emerging life sciences company (http://www.CalbaTech.com ) concentrating on the collection and banking of adult stem cells for possible future therapeutic uses, today announced the Company decreased debt by $999,926 in 2007.

CalbaTech announced revenues of $1.149 million in 2007, down slightly from $1.250 million in 2006. Gross profit in 2007 totaled $662,849. Net income in 2007 was $27,940 compared to $13,801 in 2006.

"The significant decrease in debt is a major achievement for our financial stability and our future prospects," said James DeOlden, CEO. "We are also pleased to announce that the very first harvesting of adult stem cells by LifeStem(TM) will occur at the Youthtopia Med Spa, near Atlanta, on May 10th."

Mr. DeOlden also announced that "Keller Medical Institute, the well respected medical group headquartered in Monterey, California, which is marketing and selling the LifeStem(TM) service for the collection of healthy adult stem cells for future medical use, has added three physicians to its LifeStem training program."

LifeStem(TM) is a wholly owned subsidiary of CalbaTech. The procedure it developed for the harvesting of adult stem cells uniquely involves the collection of both blood and adipose tissue. The process allows for the collection of adult stem cells in micro quantities to be cryopreserved for future transplantation into the same client, with possible future medical therapies ranging from heart disease to diabetes and other diseases that are currently difficult to treat.

About CalbaTech

CalbaTech, Inc. (OTC Bulletin Board: CLBE) is the emerging life sciences company (http://www.CalbaTech.com), concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, as well as providing services in the collection, processing and storage of adult stem cells.

Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Contact:

Paul Knopick

E&E Communications

(949) 707-5365

pknopick@eandecommunications.com


'/>"/>
SOURCE CalbaTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/18/2017)... ... January 18, 2017 , ... During ... disease to enamel erosion, and those dental problems can increase the risk of ... many pregnant women are failing to get the dental care they need. Agoura ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone wants less ... best drug option for each patient. Dentists have several general anesthesia alternatives and finding ... Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find out which ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and researchers who ... who desire a more intimate review and analysis of its highlights, a novel half-day, ... being offered by Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/17/2017)... Jan. 17, 2017 North America Insulin Delivery ... report, "North America Insulin Delivery Market Outlook to 2022", ... Delivery market. The report provides value, in millions of ... within market segments - Insulin Pens, Insulin Pumps, Insulin ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology: